The DEA raised 2026 production quotas for controlled research compounds by 67%, enabling increased supply for central nervous system clinical trials across multiple late-stage programs. This expansion reflects heightened investment in novel treatments for depression and anxiety, conditions estimated to cost more than $1 trillion in lost productivity annually.

Definium Therapeutics is among five companies advancing central nervous system candidates toward key regulatory milestones, though its specific pipeline details remain less disclosed. As treatment-resistant depression affects roughly 30% of diagnosed patients, Definium’s entry into this competitive field positions it to leverage growing clinical momentum and regulatory support.